Cite
HARVARD Citation
Cusi, K. et al. (2021). Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. Lancet gastroenterology and hepatology. pp. 889-902. [Online].